Xueqian Gong

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

Medicine, Immunology, Pharmacology +17

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Seth A. Wander, Ofir Cohen, Xueqian Gong et al. · Cancer Discovery · 2020 · 433 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster et al. · Cancer Cell · 2017 · 236 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene

Xueqian Gong, Jian Du, Stephen H. Parsons et al. · Cancer Discovery · 2018 · 233 citations

Life Sciences, Oncology, Pharmacology +17